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Abstract Recent guidelines for the diagnosis and manage-
ment of hypertension reversed the historical trend to recom-
mend lower blood pressure (BP) thresholds to diagnose hy-
pertension in high-risk individuals, such as patients with dia-
betes and elderly patients. The decision to raise the BP thresh-
olds for diagnosis of hypertension in patients with diabetes
was mostly based on the findings of the ACCORD trial.
Nonetheless, the results of the ACCORD trial are within the
predicted benefit to prevent coronary artery disease and stroke
by meta-analysis of randomized controlled trials (RCT), par-
ticularly in regard to the prevention of stroke. The Eighth Joint
National Committee (JNC 8) did not address prehypertension.
There are many RCT done in indiv iduals wi th
prehypertension and concomitant cardiovascular disease
showing the benefit of treatment of these patients. Trials
exploring the efficacy of interventions to prevent cardiovas-
cular disease in individuals with prehypertension free of car-
diovascular disease would be hardly feasible in face of the low
absolute risk of these individuals. Considering the risks of
prehypertension for cardiovascular disease and the fast pro-
gression to hypertension of a large proportion of individuals
with prehypertension, it is worth to consider drug treatment
for individuals with prehypertension. RCT showed that the
progression to hypertension can be partially halted by BP-
lowering agents. These and ongoing clinical trials are herein
revised. Prehypertension may be a window of opportunity to
prevent hypertension and its cardiovascular consequences.
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Introduction
The concept of prehypertension was proposed by the Seventh
Joint National Committee (JNC 7) [1] report and generated
controversy and new venues for research but was not ad-
dressed in the Eighth Joint National Committee (JNC 8) report
[2•]. The European guidelines maintained the definitions of
high-normal blood pressure (BP) [3] but did not recommend
the prescription of BP-lowering drugs at this stage.We believe
that that there are sound evidences to diagnose
prehypertension and to investigate the consequences and mea-
sures of control of prehypertension, including the use of
antihypertensives in selected patients.
New Thresholds for the Diagnosis of Hypertension
in the US and European Hypertension Guidelines
International guidelines for the diagnosis and management of
hypertension were recently released [2•, 3]. A historical trend
to recommend lower BP thresholds to diagnose hypertension
in high-risk individuals was unexpectedly reversed. BP targets
for the treatment were modified accordingly. Therefore,
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individuals who had hypertension before are now normoten-
sives. In the USA, the proportion of older adults (≥60 years)
with treatment-eligible hypertension decreased from 68.9 %
(95 % confidence interval (CI), 66.9–70.8 %) under JNC 7 [3]
to 61.2 % (95 % CI, 59.3–63.0 %) under the 2014 BP
guideline [4•].
European guidelines established 140/85 mmHg as the new
target to diagnose hypertension in patients with diabetes [3],
instead of 130/80 mmHg recommended by the previous
guidelines [5]. In addition, the current guideline recommends
that the drug treatment should be started at BP equal or higher
than 160 mmHg in elderly patients. The JNC 8 report [2•]
presents a radical shifting from the JNC 7 [1] in several
aspects. In regard to diagnostic thresholds and goals of treat-
ment, the JNC 8 report establishes higher diagnostic cutoff
values for BP in some conditions as well. For individuals
older than 60 years, the report established 150 mmHg of
systolic BP as the new diagnostic limit and the target of
treatment, keeping 90 mmHg for diastolic BP. For patients
with diabetes and chronic kidney disease, the current recom-
mendations are the same as those for adults without diabetes
(140/90 mmHg), in comparison with 130/80 mmHg recom-
mended in the JNC 7 report. The JNC 8 report did not address
prehypertension, a condition proposed in the JNC 7 and that is
a current focus of research, both in terms of risk for cardio-
vascular disease and therapeutic approach.
The authors of the US and the European guidelines based
their new target recommendations for BP treatment on the
results of randomized clinical trials (RCT). They should be
complimented by the initiative, which recognizes the primacy
of the results of RCT to justify medical decisions. Nonethe-
less, the results of the ACCORD trial could have another
interpretation [6•]. Moreover, they left aside the results of
many trials that were done with patients with normal BP and
cardiovascular disease, assuming that these trials were not
applicable to patients with hypertension. These and other
issues related to goals of treatment and the J-shaped phenom-
enon were recently revised [7]. In our view, the diagnostic
thresholds for the diagnosis of hypertension should not be
raised, but should be lowered. Thresholds to diagnose hyper-
tension in the upcoming years may be those currently recom-
mended for the diagnosis of prehypertension.
What the ACCORD Trial Really Shows
The ACCORD study tested the hypothesis that lowering
blood pressure beyond guideline recommendations
would confer higher cardiovascular protection [6•]. The
trial assessed the incidence of cardiovascular events in
patients with diabetes assigned to intensive therapy,
targeting systolic pressure below 120 mmHg, in com-
parison with the standard therapy, targeting systolic
pressure of less than 140 mmHg. The incidence of
coronary heart disease events—the primary endpoint—
was not statistically different between treatment arms,
and serious adverse events were three times more fre-
quent in the intensive arm. Based on these findings,
guidelines recommended 140/90 mmHg as the goal in
the management of hypertension for patients with dia-
betes. Nonetheless, the findings of the ACCORD trial
may have a different interpretation.
Relative risk reduction for cardiovascular events in the
ACCORD trial was within the predicted by the meta-
analysis of risk [8] and confirmed by the meta-analysis
of clinical trials [9]. There was a 13 % reduction in the
incidence of coronary artery disease, in comparison with
22 % predicted by the meta-analysis of clinical trials
(Fig. 1). The estimate of the meta-analysis was based in
71 studies with 9811 events, in comparison with 126
events of the ACCORD trial. For stroke, the relative risk
reduction in the ACCORD trial was identical to that
predicted by the meta-analysis of 45 studies, with 5420
events (Fig. 1). The size of benefit is remarkable, a
relative risk reduction of 41 %. The absolute incidence
of stroke in the ACCORD trial was unexpectedly low.
Taking into account that the incidence of stroke is high
worldwide and that it leads to devastating consequences,
the decision to use 140 mmHg as the goal of therapy
would be denying to patients with diabetes the benefit of
preventing a large proportion of strokes.
The Benefit of Treating Patients with Low Blood Pressure
in Patients with Subclinical or Clinical Disease
There is a proof of the concept that high blood pressure is the
major risk for cardiovascular disease [10•]. The size of benefit
in clinical trials regarding the control of high blood pressure
was within the estimations of risk provided by cohort studies.
For a reduction of 10 mmHg in systolic or 5 mmHg of
diastolic blood pressure, the relative risk reduction of coronary
heart disease was 22 % (95 % CI from 27 to 17 %) in a meta-
analysis of clinical trials, close to the estimation of reduction
of 25 % (23 to 27 %) provided by a meta-analysis of cohort
studies. The corresponding values for stroke were 41 % (33 to
48 %) in clinical trials compared to a cohort risk prediction of
36 % (34 to 38 %) [10•].
Randomized controlled trials done in patients with subclin-
ical or clinical cardiovascular disease (heart failure, stroke,
myocardial infarction, evidence of atherosclerosis, and diabe-
tes) demonstrated significant reduction of cardiovascular
events with the use of blood pressure-lowering agents inde-
pendently of baseline blood pressure [11]. Table 1 presents the
results of the more representative studies [12–19]. The benefit
of treatment was mostly attributed to blood pressure-
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independent effects of the agents tested in these studies, the so-
called pleiotropic effects. Nonetheless, the intensity of blood
pressure reduction could explain by itself the benefits of treatment.
The meta-analysis by Law and associates [9] demonstrated
that the prevention of coronary artery disease and stroke with
further reduction of blood pressurewas independent of its values
at the beginning of these trials (Fig. 2). Another meta-analysis of
25 RCT with patients with prehypertension and cardiovascular
disease [19] demonstrated that participants receiving antihyper-
tensive medication compared with controls had a mean reduc-
tion of 23 % in the incidence of stroke, 20 % in the incidence of
myocardial infarction, 29 % for fatal and nonfatal heart failure,
15 % for composite cardiovascular events, 17 % for cardiovas-
cular mortality, and 13% for all-cause mortality. Thompson and
coworkers [20] called for additional randomized trial to assess
these outcomes in patients without cardiovascular disease.
Nonetheless, these studies would be hardly feasible, in face of
the very low absolute risk of patients with prehypertension free
of cardiovascular disease. A large sample size and long time of
follow-up would be required, and it would be difficult to get
grants and persistence to doing such trial.
Preventing Full Hypertension in Patients
with Prehypertension
Besides the risks of prehypertension for cardiovascular disease,
it is a precursor of hypertension in high proportion of individ-
uals. Many studies have identified the cardiovascular risks of
prehypertension and the incidence of hypertension [21–24]. In
Porto Alegre, four in five individuals 40 to 49 years old with
prehypertension would become hypertensive in 10 years [25].
Taken together, these evidences support the view that most
guidelines moved to the wrong direction. Evidences still do
not show the whole picture and should be completed by
indirect evidences and analogous models to build the theory.
If someone wants to livemore than 100 years, he or she should
Fig. 1 Relative risk for coronary
heart disease and stroke in blood
pressure difference trials, in
epidemiological studies, and in
the ACCORD trial. Reproduced,
with permission, from reference
[9]
Table 1 Clinical trials showing the effectiveness of blood pressure-lowering drugs in the prevention of cardiovascular events in patients with normal
blood pressure
Clinical condition Studies [reference] Active treatment Primary outcome RRR
(95 % CI)
Diabetes mellitusa MICRO-HOPE [12] Ramipril MI, stroke, or CV death 25 %
(12 to 36)
Any evidence of atherosclerosis in the
coronary, cerebral, or peripheral territories
HOPE [13] Ramipril MI, stroke, or CV death 22 %
(14 to 30)b
EUROPA [14] Perindopril MI, CV death, or cardiac arrest 20 %
(9 to 29)b
Recovered from stroke PROGRESS [15] Indapamide plus perindopril Stroke 42 %
(19 to 58)
Asymptomatic heart failure SOLVED [16] Enalapril CV deaths 12 %
(−3 to 26)
Overt heart failure SOLVED [17] Enalapril CV deaths 18 %
(6 to 28)
SAVE [18] Captopril 21 %
(5 to 35)
Class IV heart failure CONSENSUS [19] Enalapril Total mortality 40 %
(P=0.002)
RRR relative risk reduction, MI myocardial infarction, CV cardiovascular
a In individuals at least 55 years old with another major cardiovascular risk factor (elevated cholesterol levels, lowHDL cholesterol, cigarette smoking, or
microalbuminuria)
b Estimate for the entire cohort, not significantly different between normotensive and hypertensive individuals
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keep blood pressure below 120 by 80 mmHg, which are the
usual BP values of worldwide centenarians.
The Efficacy of Drugs to Prevent Hypertension in Patients
with Prehypertension
Two large clinical trials showed that the prevention of hyper-
tension by drug treatment is feasible and well tolerated. In the
TROPHY study [26], 772 individuals with systolic blood
pressure between 130 and 139 mmHg or diastolic blood pres-
sure between 85 and 89 mmHg were randomized to
candesartan, 16mg daily or placebo, besides recommendations
to change lifestyle. After 2 years, the incidence of hypertension
was 66 % lower in individuals treated with candesartan (rela-
tive risk 0.34, 95 % CI 0.25–0.44). After 2 years, the treatment
was interrupted and blood pressure tended to return to the
levels of the control group. The treatment was well tolerated.
The results of the TROPHY study originated an intense
debate, mostly because of the criteria employed to diagnose
hypertension. In the total, 70 % of the diagnoses were based
on the detection of hypertensive levels at three different visits,
not necessarily consecutive, which could have resulted from
random transgressions of the prespecified thresholds on three
occasions, rather than a change in the usual blood pressure of
the patients [27]. According to Meltzer [28], the study showed
a slow unmasking of hypertension and not the prevention of
hypertension. The authors of the study TROPHY reanalyzed
data according to the JNC 7 criteria for the definition of
hypertension, confirming the original findings [29]. The au-
thors of TROPHY trial have repeatedly stated that they do not
advocate treatment of millions of people with prehypertension
worldwide, recommending further studies.
In the study PHARAO [30], 1008 individuals with systolic
blood pressure within the same values of the TROPHY trial
were randomized to ramipril 5 mg daily or no treatment.
Patients were followed-up for 3 years. The relative risk reduc-
tion for the incidence of hypertension was 34 % (hazard ratio
0.66; 95 % CI 0.53–0.81). Cough was more frequent in indi-
viduals treated with ramipril (4.8 vs. 0.4 %). The main limita-
tion of this study was its open design, which could have
increased the prescription of blood pressure-lowering drugs in
the control group or decreased the frequency of prescription in
the active treatment group. Prescription of antihypertensive
agents was one of the criteria to diagnose incident hypertension.
There is no further study published looking at the effect of
blood pressure-lowering drugs on the incidence of hyperten-
sion. Studies evaluated the effect of drug and nondrug inter-
ventions over BP in patients with prehypertension. The most
interesting one compared the effect of aspirin 100 mg admin-
istered on awakening and at bedtime and with a group sub-
mitted to lifestyle change recommendations on 48-h BP mea-
sured by ambulatory blood pressure (ABP) monitoring [31].
There was a significant decreasing of BP on ABP monitoring
among patients randomized to bedtime aspirin in comparison
with the other two groups (approximately 7 and 4 mmHg for
24-h systolic and diastolic BP, respectively).
Nebivolol apparently reduced central BP compared to pla-
cebo in a randomized controlled trial. However, the authors
did not test for the between-group differences and did not
adjust for the higher baseline values of measurements of
central hemodynamics in patients allocated to the active treat-
ment [32]. A placebo-controlled randomized controlled trial
showed no effect of aliskiren on the progression of coronary
disease in patients with prehypertension [33].
An anti-stress therapy (mindfulness-based stress reduction)
was compared with muscle relaxation training in a randomized
controlled trial. There was a small reduction of office BP in the
anti-stress therapy, but it was not confirmed by ABP monitor-
ing [34]. In a small randomized trial, continuous positive
Fig. 2 Relative risks for coronary
events and stroke in patients
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airway pressure lowered BP in patients with severe obstructive
sleep apnea and prehypertension or masked hypertension [35].
Ongoing Trials
Studies examining the benefit of drug treatment of patients
with prehypertension free of cardiovascular disease are war-
ranted [20]. There are, however, few studies underway ad-
dressing this issue. A search in the US, European, and Chinese
registers of clinical trials identified only two ongoing studies
directly related to the clinical benefits of treating
prehypertension. There are protocols for other studies in indi-
viduals with prehypertension, but none directly related to the
prevention of hypertension, target organ damage, or clinical
outcomes.
The CHINON study (http://www.chictr.org/en/proj/show.
aspx?proj=554) aims to investigate whether low-dose antihy-
pertensive treatment of with either indapamide, an angiotensin
receptor blocker (ARB), reserpine compound, or placebo
reduces the risk of cardiovascular events and development
of hypertension and diabetes in high-normal blood pressure
individuals with cardiovascular risk factors in China. In total,
10,806 subjects aged 45–79 years were randomized between
2008 and 2012. The primary endpoint is the combination of
nonfatal stroke, nonfatal myocardial infarction, and fatal car-
diovascular events. The secondary endpoints include the de-
velopment of hypertension and diabetes. Details about the
duration of the study were not reported.
We are conducting the PREVER study, a nationwide dou-
ble-blind, placebo-controlled, randomized clinical trial in Bra-
zil [36], which aims to explore the effectiveness of a low dose
of an association of diuretics over the incidence of hyperten-
sion in individuals with prehypertension free of cardiovascular
disease. The rationale is that diuretics act on the main mecha-
nism of BP elevation with age in populations, antagonizing the
loss of the kidney capacity to promote the excretion of sodium
overload without increasing BP (pressure natriuresis) [37].
Moreover, it is expected that the response to the BP-lowering
effect of diuretics may be higher before the development of
structural abnormalities in large and resistant vessels and in the
heart. The intervention aims to explore a window of opportu-
nity to prevent the development of hypertension. The trial
enrolled 724 participants who remained with prehypertension
after 3 months of lifestyle recommendations. The active treat-
ment is an association of chlorthalidone 12.5mgwith amiloride
2.5 mg. Patients have been followed-up for 18 months. The
primary outcomes are the incidence of hypertension, adverse
events, development of microalbuminuria, left ventricular hy-
pertrophy in the EKG, and diabetes. Data collection finished in
September 2014 and the results are expected to be reported in
the following months.
Conclusion
Guidelines, regulatory authorities, and researchers have been
reluctant to recommend drug interventions for individuals
with prehypertension. It is unlikely that in a foreseen future
there will be definite evidences that drug intervention in
individuals with prehypertension is the key to control the
burden of hypertension. In the mean time, partial and indirect
evidences may be used to support the idea that it is worth to
interfere at this point of the natural history of hypertension.
The results of the ongoing clinical trials may contribute to
strengthen this interpretation.
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